Insilico revenue soars above $100 million on AI drug partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals Key Takeaways: Insilico expects to power into…
InSilico lands drug discovery deal after Hong Kong IPO
The developer of AI-enabled drugs could get up to $888 million from the new deal but, without any viable products yet, its revenues rely on partner payments Key Takeaways: The…
RELATED ARTICLES
-
A healthy return: drug spin-off nets Keymed up to $320 million
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
-
Alebund soars in Hong Kong debut on kidney treatment hopes
9637.HK
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- Innovent’s $10.5 billion deal marks new model for China drugmakers
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG
